What NAD+ Actually Does. And Why Your Levels Are Already Declining.

NAD+ has become one of the most discussed molecules in longevity science. Most of what you have heard about it is either incomplete or wrong. Here is what it actually does inside your cells, why it declines so significantly after 40, and what the clinical evidence says about restoring it.

By Christine Costello  |  11 min read  |  Nourishment & Cellular Optimization

There is a molecule your body makes, uses, and recycles thousands of times per second in every cell. You have never felt it working. But you have absolutely felt what happens when there is not enough of it.

The fatigue that settles in by early afternoon. The recovery from training that takes two days instead of one. The mental sharpness that was reliably there at 35 and is noticeably less reliable at 50. The sense that your body is working harder to produce less. These are not random symptoms of getting older. They are, in significant part, the downstream effects of a molecule that peaks in early adulthood and then declines steadily for the rest of your life.

That molecule is NAD+. And understanding what it actually does, not just what supplement marketing says it does, is one of the most useful pieces of biology education available to an adult over 40.

What NAD+ Actually Is

NAD+ stands for nicotinamide adenine dinucleotide. It is a coenzyme, a molecule that enables enzymes to do their jobs, present in every living cell. It is not a vitamin, not a hormone, and not a stimulant. It is infrastructure. It is the molecular machinery through which your cells convert food into usable energy, repair their own DNA, regulate their internal clocks, and manage the inflammatory responses that determine how quickly you age.

The most accessible way to understand NAD+ is as a cellular currency. Just as a financial system requires currency to function, your cells require NAD+ to run the enzymatic reactions that power virtually everything biology does. Without adequate NAD+, those reactions slow, stall, and in some cases stop.

NAD+ exists in two forms that shuttle between each other as part of normal cellular metabolism: the oxidized form (NAD+) and the reduced form (NADH). This cycling is central to how your mitochondria produce ATP, the molecule that powers muscle contraction, nerve signaling, protein synthesis, and every other energy-demanding process your body performs. The efficiency of that cycling determines how much cellular energy you have available at any given moment.

The Four Things NAD+ Does That Matter Most

NAD+ has dozens of biological roles. Four of them are directly relevant to how a midlife body feels, performs, and ages.

These four functions are interconnected. When NAD+ declines, cellular energy production falls, sirtuin activity drops, DNA repair slows, and circadian rhythm becomes less regulated. Each of these failures compounds the others. The result is not one symptom but a cluster of them that together constitute what we tend to call aging.

Why Levels Decline So Significantly After 40

NAD+ is not simply consumed and gone. The cell recycles it through a salvage pathway that recovers NAD+ from its breakdown products and reuses it. In a young, healthy cell this recycling is efficient and NAD+ levels remain relatively stable. After 40, several things happen simultaneously that disrupt this balance.

Three factors drive this decline simultaneously. First, the enzyme NAMPT, which is the rate-limiting step in the NAD+ salvage pathway, becomes less active with age. The recycling machinery slows and NAD+ production from internal sources falls. Second, PARP enzyme activity increases with age as accumulated DNA damage demands more repair activity. PARP enzymes consume NAD+ as they work, and their increased activity in an aging cell draws down NAD+ reserves faster than the salvage pathway can replenish them. Third, CD38, an enzyme that degrades NAD+, becomes more active with age and chronic inflammation, further accelerating the depletion.

The result is a three-way squeeze: production falls, consumption rises, and degradation increases. By the time most adults reach their late fifties or early sixties, their tissue NAD+ levels may be less than half of what they were in early adulthood. And because NAD+ sits upstream of so many other cellular processes, that decline has compounding downstream effects across virtually every system in the body.

NR vs. NMN — What the Evidence Actually Shows

The two most studied NAD+ precursors currently available as supplements are nicotinamide riboside (NR) and nicotinamide mononucleotide (NMN). Both raise NAD+ levels. The differences between them matter for understanding which has stronger clinical backing at this point in the research.

NR has the longer and more robust human clinical trial record. Multiple peer-reviewed randomized controlled trials in humans have confirmed that NR supplementation safely and significantly raises blood and tissue NAD+ levels in middle-aged and older adults, with effects observed within two to four weeks at doses between 250mg and 1000mg daily.

NMN has promising preclinical data and a growing human trial base, but fewer completed randomized controlled trials in humans compared to NR at the time of writing. Both compounds enter the NAD+ biosynthesis pathway at slightly different points, but both have demonstrated meaningful NAD+ elevation in human subjects.

NR at a clinical 350mg dose delivers meaningful NAD+ precursor support backed by the most robust human clinical trial record currently available for any NAD+ precursor.

The Sirtuin Pathway in Detail

Sirtuins are often described simply as longevity proteins. That description is accurate but incomplete. There are seven sirtuin proteins in mammals (SIRT1 through SIRT7), each located in different cellular compartments and each serving distinct regulatory functions. All seven require NAD+ as a co-substrate. When they use NAD+, they produce nicotinamide as a byproduct, which feeds back into the salvage pathway to regenerate NAD+. This creates a cycle in which sirtuin activity and NAD+ availability are tightly coupled.

SIRT1 is the most studied. It is located primarily in the nucleus and cytoplasm, where it deacetylates a range of target proteins including PGC-1 alpha, the master regulator of mitochondrial biogenesis. When SIRT1 is active and well-supplied with NAD+, PGC-1 alpha is activated, new mitochondria are created to replace aging ones, and the cell maintains its energy production capacity. When NAD+ falls and SIRT1 activity declines, mitochondrial biogenesis slows, mitochondrial quality degrades, and cellular energy production falls.

SIRT3 is located in the mitochondria themselves. It regulates the efficiency of the electron transport chain directly, controlling how well mitochondria convert fuel into ATP. SIRT3 activity has been shown to decline with age in a NAD+-dependent manner, and its loss is associated with increased mitochondrial oxidative stress and reduced metabolic efficiency.

PARP Enzymes and the DNA Repair Drain

PARP1 and PARP2 are the primary DNA repair enzymes in the nucleus. Each time they detect and repair a DNA strand break, they consume NAD+ molecules in the process. In a young cell with low levels of accumulated DNA damage and high NAD+ production, this consumption is easily compensated. In an aging cell with higher levels of accumulated damage, more active PARP enzymes, and falling NAD+ production, the math shifts dramatically.

The research of David Sinclair at Harvard has drawn particular attention to the PARP-sirtuin competition for NAD+. When DNA damage is high and PARP enzymes are running at elevated activity to address it, they compete directly with sirtuins for the available NAD+ pool. This means that elevated DNA damage does not just consume NAD+. It actively reduces the NAD+ available for sirtuin function, epigenetic maintenance, and mitochondrial biogenesis. Two hallmarks of aging, genomic instability and mitochondrial dysfunction, are thus biochemically linked through their shared dependence on NAD+.

What This Means For You Practically

The biology is complex. The practical application is not.

If you are over 40, your NAD+ levels are already lower than they were at 30. This is not speculation. It is the consistent finding across tissue NAD+ measurement studies in aging human subjects. The question is not whether you are experiencing NAD+ decline. The question is by how much, and what you are doing to address it.

Diet alone will not restore NAD+ to youthful levels. Tryptophan and niacin from food contribute to NAD+ production through the de novo synthesis pathway. But the rate-limiting enzyme in this pathway, NAMPT, becomes less active with age regardless of dietary intake. Food is a foundation, not a restoration strategy for meaningful NAD+ decline.

NR at a clinical dose is the most evidence-supported oral NAD+ restoration strategy currently available. 350mg delivers a dose within the range used in human clinical trials demonstrating significant NAD+ elevation. Lower doses produce smaller effects. Higher doses have been studied safely but offer diminishing returns in most adults.

Resistance training supports NAD+ metabolism independently. Exercise activates AMPK, which in turn stimulates NAMPT activity and supports the salvage pathway. This is one of the mechanisms through which resistance training produces systemic benefits that extend well beyond the muscle being trained. It is also why combining exercise with NR supplementation is more effective than either alone for supporting NAD+ levels and mitochondrial health in aging adults.

The Bottom Line

NAD+ is not a wellness trend. It is not a biohacker ingredient or a longevity fad. It is one of the most fundamental molecules in human biology, with a well-documented decline trajectory after 40 and a growing clinical evidence base supporting its restoration through NR supplementation.

The fatigue, the reduced recovery, the sleep disruption, the metabolic changes of midlife are not random. They are, in meaningful part, expressions of a cellular energy and repair system that is running at a fraction of its earlier capacity because the molecule that powers it has been allowed to decline without intervention.

That decline is addressable. The evidence is there. The clinical doses are known. And for an adult over 40 who is serious about maintaining the physiological capacity to train, recover, and age well, restoring NAD+ is not optional supplementation. It is foundational cellular maintenance.